gefitinib has been researched along with n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide) | Trials (n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide) | Recent Studies (post-2010) (n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 109 | 0 | 11 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Dang, YW; He, RQ; Luo, DZ; Xiong, DD; Xu, WQ | 1 |
1 other study(ies) available for gefitinib and n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide
| Article | Year |
|---|---|
In silico analysis identified miRNA‑based therapeutic agents against glioblastoma multiforme.
Topics: Androstadienes; Antineoplastic Agents; Brain Neoplasms; Computational Biology; Drug Discovery; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glioblastoma; Humans; MicroRNAs; Molecular Docking Simulation; Molecular Targeted Therapy; Sulfonamides; Transcriptome | 2019 |